Most medical device cos likely to achieve Q3 results targets- JPM

AtriCure

08/09/2021 11:25

** J.P. Morgan believes most medical device cos in its
coverage can achieve their Q3 results estimates, as they have
already taken into account some disruption to procedures from
fast-spreading Delta coronavirus variant in H2
    ** However, brokerage is concerned about Zimmer Biomet
Holdings  ZBH.N , which offers devices for deferrable procedures
such as hip and knee surgeries and which require greater
hospital stays
    ** Brokerage is also less confident about Integra
Lifesciences  IART.O  and Nuvasive Inc  NUVA.O , given their
exposure to hospitalizations and deferrable procedures,
respectively, and as their H2 outlook is less conservative than
their peers
    ** Among large-cap medtech cos, brokerage is most optimistic
about Abbott Labs  ABT.N , Becton Dickinson  BDX.N , Boston
Scientific Corp  BSX.N , Dexcom  DXCM.O  and Edwards
Lifesciences  EW.N 
    ** Among small and mid-cap companies, brokerage thinks
Inspire Medical Systems Inc  INSP.N , Insulet Corp  PODD.O ,
Cooper companies  COO.N , and Penumbra Inc  PEN.N  are likely to
beat their forecast
    ** AtriCure Inc  ATRC.O , Eargo Inc  EAR.O , iRhythm
Technologies  IRTC.O , Glaukos Corp  GKOS.N  and Silk Road
Medical  SILK.N  well-positioned among small caps - brokerage

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))